Craig Hallum Initiates Coverage on Certara (NASDAQ:CERT)

Stock analysts at Craig Hallum assumed coverage on shares of Certara (NASDAQ:CERT) in a research report issued on Monday, MarketBeat Ratings reports. The firm set a “buy” rating on the stock.

CERT has been the subject of several other reports. UBS Group decreased their price objective on shares of Certara from $17.50 to $15.00 and set a “buy” rating for the company in a report on Thursday, August 7th. Zacks Research upgraded shares of Certara from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. Morgan Stanley began coverage on shares of Certara in a research note on Thursday, July 3rd. They issued an “equal weight” rating and a $16.00 price target for the company. Finally, KeyCorp decreased their price target on shares of Certara from $18.00 to $15.00 and set an “overweight” rating for the company in a research note on Monday, July 14th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.25.

Certara Stock Up 0.3%

Shares of NASDAQ CERT opened at $12.22 on Monday. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.27. Certara has a 12 month low of $8.64 and a 12 month high of $15.69. The firm has a market capitalization of $1.96 billion, a PE ratio of 244.45 and a beta of 1.43. The firm has a fifty day simple moving average of $10.94 and a two-hundred day simple moving average of $11.29.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a return on equity of 5.11% and a net margin of 1.97%.The company had revenue of $104.57 million during the quarter, compared to the consensus estimate of $104.14 million. During the same quarter last year, the company posted $0.07 earnings per share. The firm’s revenue for the quarter was up 12.1% compared to the same quarter last year. Equities analysts expect that Certara will post 0.28 earnings per share for the current year.

Insiders Place Their Bets

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total transaction of $559,366.08. Following the completion of the sale, the insider directly owned 73,979 shares in the company, valued at approximately $807,850.68. This trade represents a 40.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 2.33% of the company’s stock.

Institutional Trading of Certara

Institutional investors have recently made changes to their positions in the stock. AdvisorNet Financial Inc purchased a new stake in shares of Certara during the 2nd quarter valued at about $25,000. Versant Capital Management Inc boosted its holdings in shares of Certara by 218.8% during the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company’s stock valued at $27,000 after acquiring an additional 1,866 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Certara during the 1st quarter valued at about $31,000. AlphaQuest LLC purchased a new stake in shares of Certara during the 1st quarter valued at about $39,000. Finally, Osaic Holdings Inc. boosted its holdings in shares of Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after acquiring an additional 1,175 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.